Procedure Deep-Dive · November 19, 2026

Factor V Leiden and Cosmetic Surgery: Inherited Thrombophilia, Antiphospholipid Syndrome, Estrogen, Enoxaparin, Tummy Tucks, and Liposuction

Factor V Leiden is the most common inherited clotting tendency in people of European ancestry, and most carriers never have a clot. Add a long tummy tuck, a mommy makeover, estrogen, and a flight home, and the arithmetic changes. Here is how surgeons should score the risk, why the test result matters less than the family history, what antiphospholipid syndrome adds, why MTHFR is a distraction, and how blood thinners and hematoma risk get traded against each other.

By The Editorial Desk

17 min read

A woman with short dark curly hair and small hoop earrings, wearing a loose heather-gray knit sweater, standing beside a tall white-framed window with one hand resting on the sill, a vase of dried flowers, a glass of water, and folded papers on a wooden desk behind her, looking at the camera with a calm, thoughtful expression

She is 38, two children in, and wants a tummy tuck with liposuction of the flanks and a breast lift in the same sitting. On the intake form, under "family history," she wrote one line almost as an afterthought: her mother had a clot in her leg after a hip operation, and a cousin was told she carries "a clotting gene" after a miscarriage. She has never had a clot herself. She takes a combined birth control pill. She has a flight booked to visit her sister ten days after surgery. Nobody in the first consultation asked a follow-up question about any of it.

Each item on that list is ordinary. Taken together, they describe one of the more predictable ways an elective operation goes wrong. The cousin's "clotting gene" is very likely Factor V Leiden or the prothrombin gene mutation, the two most common inherited thrombophilias. The patient has a reasonable chance of carrying the same thing. And the procedure she wants, a long combined abdominoplasty, sits at the top of the clot-risk table for cosmetic surgery. None of this means she cannot have the operation. It means the operation should be planned by someone who has done the arithmetic. Our general piece on blood clots after plastic surgery covers the basics of venous thromboembolism. This one is for the patient whose family history, or whose own lab report, already says the blood leans toward clotting.

What inherited thrombophilia actually is, and how common it is

The short answer: inherited thrombophilia is a family of genetic variants that tilt the clotting system toward forming clots, the most common being Factor V Leiden and the prothrombin G20210A mutation, and most people who carry one will never have a clot unless something else, such as surgery, estrogen, pregnancy, or immobility, is stacked on top.

Blood clotting is a balance between proteins that build a clot and proteins that switch the process off. Factor V Leiden is a single change in the gene for clotting factor V that makes the protein resistant to being shut down by activated protein C, one of the body's main brakes. The clot-building signal stays on longer than it should. The prothrombin G20210A mutation works differently: it raises the amount of prothrombin circulating in the blood, so there is simply more raw material available to make a clot.

These are not rare curiosities. Factor V Leiden is carried by roughly 3 to 8 percent of people of European ancestry, according to figures summarized by the National Institutes of Health's MedlinePlus Genetics, and is much less common in people of African, East Asian, and Indigenous American ancestry. The prothrombin mutation is found in roughly 2 percent of people of European descent. Most carriers have one copy of the variant (heterozygous), which raises the lifetime risk of a vein clot several-fold compared with noncarriers. People with two copies (homozygous), or with one copy of each variant, carry a considerably higher risk.

A second group of inherited conditions is rarer but more potent: deficiencies of the natural anticoagulants antithrombin, protein C, and protein S. Antithrombin deficiency in particular is regarded by hematologists as one of the highest-risk inherited thrombophilias, and families with it often have clots at young ages and with relatively minor triggers.

Then there is a condition that behaves like a thrombophilia but is acquired rather than inherited. Antiphospholipid syndrome is an autoimmune disorder in which the body makes antibodies (lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies) that make the blood prone to clotting in veins and, unlike Factor V Leiden, in arteries as well. It can cause strokes, heart attacks, and recurrent pregnancy loss, and it frequently travels with lupus, which our piece on cosmetic surgery with autoimmune disease covers in broader terms. It is diagnosed by blood tests that must be positive on two occasions at least 12 weeks apart, because these antibodies can appear briefly after infections and then vanish.

The most important idea in this whole topic is that the variant is a loaded spring, not a trigger. Plenty of Factor V Leiden carriers live into old age without a single clot. Clots in carriers cluster around the moments when the other sides of the clotting triangle are pushed at the same time: blood that is not moving, vessel walls that are injured, and blood chemistry that has shifted. Major surgery delivers all three at once. Estrogen and pregnancy deliver the third. That is why cosmetic surgery is exactly the setting where a quiet genetic variant stops being quiet.

Why the family history matters more than the test result

The short answer: a personal or family history of clots predicts risk better than a positive genetic test alone, so a carrier with no clots in the family and a noncarrier whose mother and sister both had unexplained clots can land in surprisingly similar places, and the surgeon who only asks "have you been tested?" is asking the wrong question.

Patients often arrive in one of two states. Some have a lab report showing heterozygous Factor V Leiden, found because a relative was diagnosed, and they are anxious that it rules them out of surgery. Others have a family full of clots and have never been tested at all, and they assume that no diagnosis means no problem. Both assumptions are off.

Hematologists have moved away from treating the genetic result as the main event. Clot risk clusters in families beyond what the known variants explain, which means a strong family history carries information that testing does not capture. The American Society of Hematology's 2023 guideline on thrombophilia testing takes a selective stance: testing is suggested in specific situations where a result would actually change management, such as some women with a family history of high-risk thrombophilia who are considering estrogen or pregnancy, rather than as a routine screen for everyone. Broad screening of healthy people before surgery is not recommended by the major hematology and surgical bodies.

The questions that matter at a consultation are concrete:

  • Have you ever had a clot in a leg vein, lung, or anywhere else, including one that was called "superficial" or "just a vein"?
  • Has a parent, sibling, or child had one? Was it before age 50? Was it unprovoked, meaning it happened without surgery, a cast, a long hospital stay, or cancer?
  • Has anyone in the family been told they carry Factor V Leiden, a prothrombin mutation, antithrombin deficiency, protein C or protein S deficiency, or antiphospholipid antibodies?
  • Have you had recurrent miscarriages, a stillbirth, or severe preeclampsia that led a doctor to check for clotting problems?
  • Are you on estrogen in any form: a combined pill, patch, or ring, hormone therapy for menopause, or gender-affirming estrogen?

A careful surgeon treats a "yes" to any of these as the beginning of a conversation, not a form field. If a relative has a known diagnosis, the specific variant matters: a family history of antithrombin deficiency warrants a hematology opinion before any significant operation, while a single heterozygous Factor V Leiden carrier with no personal history may simply move up a risk tier. Our piece on preoperative testing before cosmetic surgery explains why ordering a panel of tests "just to be safe" can create more confusion than clarity, and thrombophilia testing is a textbook example.

There are practical traps in the testing itself. The genetic tests for Factor V Leiden and the prothrombin mutation are reliable at any time, because DNA does not change. The blood levels of antithrombin, protein C, and protein S are not: they drop during an acute clot, during pregnancy, with estrogen use, with liver disease, and in response to anticoagulants such as warfarin and heparin. A protein S level drawn while someone is on the pill or warfarin can falsely suggest a deficiency. This is one reason a hematologist, not a cosmetic practice, should order and interpret anything beyond the genetic tests.

And one test patients often bring in should be set aside. MTHFR gene variants are extremely common and were once thought to raise clot risk through homocysteine levels. The American College of Medical Genetics and Genomics has recommended against MTHFR testing as part of a thrombophilia evaluation, because the common variants have not been shown to meaningfully raise clot risk. A patient who was told by a wellness clinic that she has "the MTHFR clotting gene" should not be scored as if she has Factor V Leiden, and should not be sold supplements on that basis. If anything, the supplement list deserves its own review; our supplements stop list covers what actually matters before surgery.

How the risk adds up: procedure, hours, estrogen, and the flight home

The short answer: surgeons score clot risk with the Caprini model, in which a known thrombophilia, a family history of clots, and a personal history of clots each add substantial points, and those points stack with age, body mass index, the length of the operation, estrogen use, and the type of procedure, with abdominoplasty and long combined cases at the high end.

The American Society of Plastic Surgeons' venous thromboembolism task force recommended that plastic surgeons use a formal risk assessment, and the Caprini Risk Assessment Model is the one most widely used and validated in plastic surgery patients. It assigns points for age, operation length, obesity, recent pregnancy, estrogen use, prior clots, family history, and a list of specific thrombophilias. In the standard version, Factor V Leiden, the prothrombin mutation, lupus anticoagulant, anticardiolipin antibodies, and "other congenital or acquired thrombophilia" each carry 3 points. A personal history of clots carries 3. A family history of clots carries 3. Major surgery lasting more than 45 minutes adds 2. So a healthy 38-year-old having a three-hour combined procedure who carries Factor V Leiden and has a mother with a clot can reach a high-risk score before her weight, birth control, or recent pregnancy are even counted.

The numbers behind those tiers are sobering. In the validation work led by Christopher Pannucci and colleagues, published in plastic surgery journals, clot rates in patients who did not receive blood-thinning medication climbed steeply with Caprini score, reaching roughly one in ten in the highest tier. Those were mostly inpatients having larger operations than a typical outpatient cosmetic case, but the gradient is the point: risk is not a fixed property of the operation, it is a property of the patient plus the operation.

Several features of cosmetic surgery push in the wrong direction at once:

  • Abdominoplasty is the high-risk cosmetic procedure. Among aesthetic operations, tummy tucks consistently carry the highest reported rate of vein clots and pulmonary embolism, likely because of operative length, tightening of the abdominal wall, the bent-at-the-waist recovery position, and reduced walking in the first days. Whether a mini tummy tuck or a full abdominoplasty is on the table matters less than the total hours and how much the abdominal wall is tightened.
  • Combined procedures multiply exposure. Adding breast surgery and liposuction to a tummy tuck extends anesthesia time, and insurance-based data on cosmetic complications have repeatedly shown higher clot rates in combined cases. Our piece on how many procedures belong in one surgery explains why staging is sometimes the safety decision rather than the scheduling one.
  • Estrogen interacts with the genetics. Combined estrogen-containing contraceptives raise clot risk on their own. In a Factor V Leiden carrier, the effect is multiplicative rather than additive, which is the strongest argument for planning around them. The details of when and how to stop are covered in our piece on birth control before cosmetic surgery.
  • Recent pregnancy counts. The weeks after delivery are among the highest-risk periods for clots in a woman's life, and a thrombophilia amplifies that. A mommy makeover planned too soon after pregnancy stacks the postpartum effect on top of the surgical one.
  • The flight home. Long-haul travel adds immobility and dehydration in the exact window when a postoperative clot is most likely to form. For carriers, the logistics of surgery abroad are not merely a cost issue.

Liposuction alone, particularly smaller-volume cases under local anesthesia, sits lower on the table, and some surgeons point to awake liposuction as one way to reduce anesthesia time and keep the patient mobile. That is a reasonable consideration, not a guarantee: high-volume liposuction under general anesthesia is still major surgery from the clot's point of view. Gluteal fat grafting carries its own distinct embolism risk (fat entering the veins of the buttock), which is a different mechanism from a vein clot and is covered in our piece on Brazilian butt lift safety protocols; a thrombophilia does not change that fat embolism risk, but it does add to the ordinary clot risk of a long, prone operation.

"

A Factor V Leiden result is a loaded spring, not a trigger. The surgery, the estrogen, the recent pregnancy, and the flight home are the triggers, and a careful plan removes as many of them as it can.

"

The prevention plan: mechanical, medication, and the hematoma trade

The short answer: for a patient with a known thrombophilia or strong family history, the standard package is compression devices during surgery, walking within hours, shortened operating time, stopping estrogen ahead of time, and in most higher-risk cases a course of low-molecular-weight heparin such as enoxaparin, with the explicit understanding that blood thinners modestly raise the risk of a hematoma that may need a return to the operating room.

The mechanical measures are close to universal and costless in every sense that matters. Sequential compression sleeves on the calves should be running before anesthesia begins and should stay on until the patient is walking. Early ambulation, meaning getting up and walking within hours of surgery and every hour or two while awake, is the single most repeated instruction in the guidance. Compression stockings, adequate hydration, and positioning that avoids prolonged bending at the hips all help. Our piece on compression garments separates what the evidence supports for swelling and contour from what supports clot prevention, which are different questions.

The harder decision is medication. Chemoprophylaxis, usually a daily injection of enoxaparin, reduces clot rates in high-risk plastic surgery patients. It also raises the rate of bleeding and hematoma. In aesthetic surgery, a hematoma is not trivial: in a tummy tuck or breast surgery it can mean another trip to the operating room, a transfusion in rare cases, and threatened skin. In a facelift, as our piece on hematoma after facelift explains, it can threaten the skin flaps themselves. The plastic surgery literature on enoxaparin dosing reflects this tension; some groups adjust dose by weight and check anti-factor Xa levels to avoid both underdosing and overdosing.

For a known thrombophilia carrier having a tummy tuck or combined procedure, the balance usually tips toward medication. The questions to ask are specific:

  • When does it start? Many protocols begin the first dose after surgery, once the surgeon is satisfied with bleeding control, rather than before.
  • How long does it last? Courses range from a few days to several weeks depending on the score; extended prophylaxis is more common for the highest tiers.
  • Who teaches the injections? Patients often go home on enoxaparin, and someone in the recovery house or caregiver plan needs to know how and when to give it.
  • What about tranexamic acid? Many surgeons now use tranexamic acid to reduce bleeding and bruising. It reduces the breakdown of clots rather than promoting their formation, and large studies in surgery have not shown a clear rise in vein clots, but a patient with a strong thrombophilia history should hear her surgeon's explicit reasoning for using it or not.

Patients already on long-term anticoagulation are a different group. A person with antiphospholipid syndrome or a prior unprovoked clot on lifelong warfarin or a direct oral anticoagulant has to pause it for surgery and restart it afterward, and the timing is a joint decision with the prescribing hematologist. Our piece on blood thinners before cosmetic surgery walks through how that pause and restart is usually handled. One detail matters specifically for antiphospholipid syndrome: guidance from hematology bodies has warned against using direct oral anticoagulants in high-risk antiphospholipid syndrome, particularly when all three antibody tests are positive, after a trial found more arterial clots with rivaroxaban than with warfarin. A patient whose regimen is being changed for surgery should not be switched to a different drug without her hematologist's input.

It is also worth contrasting these patients with ones whose risk runs the other way. A patient with von Willebrand disease or a hemophilia carrier state, covered in our piece on bleeding disorders and cosmetic surgery, needs the opposite plan. And patients with blood cancers that raise both clotting and bleeding risk, such as those described in our piece on polycythemia vera and essential thrombocythemia, sit on both sides of the balance at once.

Estrogen, pregnancy, and the calendar around surgery

The short answer: for thrombophilia carriers, the calendar matters as much as the operating room, which means stopping estrogen-containing contraceptives or oral hormone therapy weeks ahead under a plan that prevents pregnancy, waiting well beyond the postpartum window, and building travel and return to activity around the clot-risk period rather than around vacation days.

Estrogen is the most modifiable risk factor these patients carry. Combined pills, patches, and rings all contain estrogen, and in carriers of Factor V Leiden the clot risk from estrogen is magnified. Surgeons commonly ask patients to stop estrogen-containing contraception about four weeks before major surgery, which is long enough for its clotting effects to wear off. That creates an obvious problem: an unplanned pregnancy is not a safer outcome. A progestin-only method or a nonhormonal method is the usual bridge, chosen with the patient's gynecologist.

Menopausal hormone therapy raises a related question. Oral estrogen raises clot risk more than estrogen delivered through the skin, and observational data suggest transdermal estrogen carries little or no added clot risk at standard doses. Some surgeons ask patients to pause oral hormone therapy before major surgery and are more relaxed about patches, but the decision depends on the dose, the indication, and the patient's overall score. For transgender women on gender-affirming estrogen, the question is handled more carefully still, because stopping hormones has real costs; our piece on gender-affirming top surgery touches on how teams individualize that decision.

Pregnancy history carries two kinds of information. First, a history of recurrent pregnancy loss, stillbirth, or severe placental problems sometimes leads to a diagnosis of antiphospholipid syndrome, and patients who were treated with heparin during pregnancy should mention it. Second, the postpartum period itself is high risk. Clot risk after delivery is highest in the first weeks and gradually returns toward baseline over the following months. Most surgeons already ask mothers to wait at least six months after delivery and after breastfeeding ends before a mommy makeover, for reasons of tissue recovery; for thrombophilia carriers, the clotting argument for patience adds to it. Patients considering pregnancy after a tummy tuck who carry a thrombophilia should also expect obstetric planning that may include heparin during pregnancy, which is a separate conversation with an obstetrician.

The rest of the calendar is mostly about movement. Walking matters from day one. Returning to normal daily activity is encouraged early even when heavy exercise is not; our piece on when you can exercise after plastic surgery separates walking (always encouraged) from strenuous activity (staged). Long flights in the first weeks are worth postponing for carriers. If travel cannot be avoided, the surgeon should know in advance, and the plan may include an extended course of medication, compression stockings, aisle seating, and regular walking during the flight.

Patients on weight-loss medications deserve a brief note. Rapid weight loss changes body composition and may change dosing calculations for enoxaparin, and GLP-1 drugs carry their own anesthesia considerations, discussed in our piece on GLP-1 drugs before plastic surgery. None of that makes the drugs off-limits; it just means the medication list must be complete.

Finally, every patient with a thrombophilia should know the warning signs well enough to act on them without waiting for a scheduled follow-up: one-sided calf or thigh swelling, pain, warmth, or redness; sudden shortness of breath; chest pain that worsens with breathing; a racing heart; coughing blood; or unexplained fainting. The swelling expected after liposuction is usually symmetric and gradually improving; a clot is typically one-sided and worsening. For antiphospholipid syndrome, which can cause arterial clots, the warning list also includes stroke symptoms. These are emergency-room symptoms, not phone-message symptoms.

The honest summary

Factor V Leiden and its relatives are common, usually silent, and very relevant to cosmetic surgery. Most carriers will go through life without a clot. But elective surgery is one of the few situations where people knowingly stack risk factors together, and a long tummy tuck, a combined mommy makeover, a recent pregnancy, estrogen, and a flight home are exactly the stack that turns a quiet variant into a pulmonary embolism. The good news is that every item on that list except the genetics can be changed.

For patients, the most useful thing is not a new test. It is a complete history, told plainly: any clot you have ever had, any relative who had one, any diagnosis a relative carries, any pregnancy losses that led to blood work, and every form of estrogen you take. If you already have a lab report, bring it. If you were told you have an MTHFR variant, know that it is not scored like Factor V Leiden. If a relative has antithrombin deficiency or antiphospholipid syndrome, or if you have had a clot yourself, ask for a hematology opinion before surgery is scheduled. Keep a copy of your own records; our piece on medical records after cosmetic surgery explains why that matters if anything goes wrong later.

For surgeons, the standard is clear enough to be audited: a documented risk score, mechanical prevention for every major case, early walking, a deliberate decision about chemoprophylaxis that names the hematoma trade-off, a plan for estrogen that does not create an unplanned pregnancy, and a willingness to shorten or stage a combined operation when the score is high. A practice that has a written protocol for these patients will explain it readily. One that answers "do you worry about my clotting gene?" with "we see it all the time" has not answered the question. If you are not hearing a specific plan, a second consultation is cheap insurance compared with the complication it is meant to prevent.